The discovery of CCR3/H1 dual antagonists with reduced hERG risk
Year: 2012
Type: article
Institution: AstraZeneca (United Kingdom)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2079110646
